Indeed! It is all about POTENTIAL and I have 250K shares. Sold everything and bought back when it hit the lows recently, thus have recovered some of my investment and reduced my cost basis.
Just considering a few facts -
1) that it addresses Hepatitis 2) number of people affected on a global scale (HUGE) 3) initial promise in the trials... not to forget the advantage of reduced side effects compared to competition , or the reduced dosage (either way you take it - seems to be favorable) 4) and of course a CEO who has credibility
I have seen strange things happen in biotech as far as pps is concerned ( both the good and the ugly). No surprise if this baby hits double digits as and when the results come out and then we get a buy out - just because big pharma wants it badly (for all the good reasons you can think of)
Give it a couple of years and we will be laughing at the current low price of the stock
News 
Market Data 
Discover 
